Loading...
Header Logo
Keywords
Last Name
Institution

ELIZABETH A GRIMM

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. 2019 Mar 01; 25(5):1650-1663. PMID: 30538110.
      View in: PubMed
    2. Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 12; 2:1-12. PMID: 30652536.
      View in: PubMed
    3. McKean M, Oba J, Ma J, Roth KG, Wang WL, Macedo MP, Carapeto FCL, Haydu LE, Siroy AE, Vo P, Hong DS, Eterovic AK, Patel KP, Bassett RL, Grimm EA, Lazar AJ, Woodman SE. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 Mar; 139(3):728-731. PMID: 30798855.
      View in: PubMed
    4. Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H. Mitochondrial dynamic alterations regulate melanoma cell progression. J Cell Biochem. 2018 Sep 06. PMID: 30256441.
      View in: PubMed
    5. Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J, Eterovic AK, Sen S, Kale CR, Yu X, Haymaker CL, Routbort M, Haydu LE, Bernatchez C, Lazar AJ, Grimm EA, Hong DS, Woodman SE. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018. PMID: 30094412.
      View in: PubMed
    6. Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Front Oncol. 2018; 8:67. PMID: 29616189.
      View in: PubMed
    7. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689. PMID: 28670312.
      View in: PubMed
    8. Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. PLoS One. 2017; 12(4):e0176763. PMID: 28453553.
      View in: PubMed
    9. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565.
      View in: PubMed
    10. Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C. Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression. Melanoma Res. 2017 04; 27(2):126-133. PMID: 28118269.
      View in: PubMed
    11. Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia. 2017 03; 19(3):237-249. PMID: 28254151.
      View in: PubMed
    12. Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Hum Vaccin Immunother. 2017 05 04; 13(5):1105-1108. PMID: 28121247.
      View in: PubMed
    13. Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Sci Rep. 2016 10 20; 6:35848. PMID: 27762323.
      View in: PubMed
    14. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol Res. 2016 11; 4(11):983-994. PMID: 27697858.
      View in: PubMed
    15. Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Mol Cancer Ther. 2016 10; 15(10):2442-2454. PMID: 27458138.
      View in: PubMed
    16. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7. PMID: 24977319.
      View in: PubMed
    17. Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res. 2016 May; 29(3):297-308. PMID: 26801201.
      View in: PubMed
    18. Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. 2016 08 01; 122(15):2299-312. PMID: 26991400.
      View in: PubMed
    19. Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA. Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073. PMID: 26986135.
      View in: PubMed
    20. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24. PMID: 26783288.
      View in: PubMed
    21. Grimm EA. Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance. Crit Rev Oncog. 2016; 21(1-2):57-63. PMID: 27481002.
      View in: PubMed
    22. Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB. IL-10: Expanding the Immune Oncology Horizon. Receptors Clin Investig. 2015; 2(4). PMID: 26661378.
      View in: PubMed
    23. Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov. 2015 Dec; 5(12):1314-27. PMID: 26450788.
      View in: PubMed
    24. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2901. PMID: 26178706.
      View in: PubMed
    25. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-?. J Invest Dermatol. 2015 Nov; 135(11):2775-2784. PMID: 26039541.
      View in: PubMed
    26. Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, Woodman SE. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res. 2015 May; 28(3):357-9. PMID: 25515650.
      View in: PubMed
    27. Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA. Inflammatory IL-1ß-driven JNK activation in stage III melanoma. Pigment Cell Melanoma Res. 2015 Mar; 28(2):236-9. PMID: 25546243.
      View in: PubMed
    28. Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Transl Oncol. 2014 Aug; 7(4):484-92. PMID: 24969538.
      View in: PubMed
    29. Chattopadhyay C, Grimm EA, Woodman SE. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. PLoS One. 2014; 9(2):e83957. PMID: 24551032.
      View in: PubMed
    30. Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014 Feb 15; 74(4):1067-78. PMID: 24398473.
      View in: PubMed
    31. Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA. Expression of leptin and iNOS in oral melanomas in dogs. J Vet Intern Med. 2013 Sep-Oct; 27(5):1278-82. PMID: 24033424.
      View in: PubMed
    32. Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clin Cancer Res. 2013 Oct 15; 19(20):5557-63. PMID: 23868870.
      View in: PubMed
    33. Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res. 2013 May; 26(3):422-5. PMID: 23360207.
      View in: PubMed
    34. Li C, Yin M, Wang LE, Amos CI, Zhu D, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21. PMID: 23407396.
      View in: PubMed
    35. Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell Melanoma Res. 2013 Jan; 26(1):97-112. PMID: 23020131.
      View in: PubMed
    36. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40. PMID: 22850568.
      View in: PubMed
    37. Shirley SH, Grimm EA, Kusewitt DF. Ultraviolet radiation and the slug transcription factor induce proinflammatory and immunomodulatory mediator expression in melanocytes. J Skin Cancer. 2012; 2012:410925. PMID: 22745913.
      View in: PubMed
    38. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833. PMID: 22558101.
      View in: PubMed
    39. Shirley SH, Greene VR, Duncan LM, Torres Cabala CA, Grimm EA, Kusewitt DF. Slug expression during melanoma progression. Am J Pathol. 2012 Jun; 180(6):2479-89. PMID: 22503751.
      View in: PubMed
    40. Liu H, Wei Q, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wang LE. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75. PMID: 22198560.
      View in: PubMed
    41. Lee I, Fox PS, Ferguson SD, Bassett R, Kong LY, Schacherer CW, Gershenwald JE, Grimm EA, Fuller GN, Heimberger AB. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44. PMID: 22488042.
      View in: PubMed
    42. Jen EY, Poindexter NJ, Farnsworth ES, Grimm EA. IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. Melanoma Res. 2012 Feb; 22(1):19-29. PMID: 22027907.
      View in: PubMed
    43. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer. 2012 Jul 15; 131(2):E56-65. PMID: 22020736.
      View in: PubMed
    44. Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer. 2012 Aug 15; 131(4):891-901. PMID: 21953496.
      View in: PubMed
    45. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res. 2011 Nov; 9(11):1537-50. PMID: 21954434.
      View in: PubMed
    46. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, MacGregor S, Hayward NK, Martin NG, Duffy DL, Mann GJ, Cust A, Hopper J, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011 Dec 15; 20(24):5012-23. PMID: 21926416.
      View in: PubMed
    47. Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutr Cancer. 2011; 63(6):940-9. PMID: 21745040.
      View in: PubMed
    48. Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Res. 2011 Feb; 21(1):44-56. PMID: 20216471.
      View in: PubMed
    49. Shanker M, Jin J, Branch CD, Miyamoto S, Grimm EA, Roth JA, Ramesh R. Tumor suppressor gene-based nanotherapy: from test tube to the clinic. J Drug Deliv. 2011; 2011:465845. PMID: 21490751.
      View in: PubMed
    50. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35. PMID: 20975100.
      View in: PubMed
    51. Poindexter NJ, Williams RR, Powis G, Jen E, Caudle AS, Chada S, Grimm EA. IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytes. Exp Dermatol. 2010 Aug; 19(8):714-22. PMID: 20545760.
      View in: PubMed
    52. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15. PMID: 20655738.
      View in: PubMed
    53. Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep. 2010 Apr; 23(4):901-7. PMID: 20204272.
      View in: PubMed
    54. Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44. PMID: 20215556.
      View in: PubMed
    55. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol. 2009 Jun; 129(6):1483-8. PMID: 19037234.
      View in: PubMed
    56. Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA. Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol. 2009 Mar; 181(3):1028-34; discussion 1034. PMID: 19150565.
      View in: PubMed
    57. Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008 Dec; 7(12):3842-51. PMID: 19056673.
      View in: PubMed
    58. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51. PMID: 18563783.
      View in: PubMed
    59. Kong LY, Wei J, Sharma AK, Barr J, Abou-Ghazal MK, Fokt I, Weinberg J, Rao G, Grimm E, Priebe W, Heimberger AB. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32. PMID: 19002459.
      View in: PubMed
    60. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, Fuller GN, Fokt I, Grimm EA, Schmittling RJ, Archer GE, Sampson JH, Priebe W, Heimberger AB. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68. PMID: 18794085.
      View in: PubMed
    61. Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5. PMID: 18626307.
      View in: PubMed
    62. Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol. 2009 Jan; 129(1):148-54. PMID: 18668140.
      View in: PubMed
    63. Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 2008 Jul; 43(1):34-44. PMID: 18511292.
      View in: PubMed
    64. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84. PMID: 18183598.
      View in: PubMed
    65. Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide. 2008 Sep; 19(2):133-7. PMID: 18472017.
      View in: PubMed
    66. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8. PMID: 18049450.
      View in: PubMed
    67. Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8. PMID: 17328085.
      View in: PubMed
    68. Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemother Pharmacol. 2007 Oct; 60(5):625-33. PMID: 17195067.
      View in: PubMed
    69. Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J Interferon Cytokine Res. 2006 Dec; 26(12):877-86. PMID: 17238830.
      View in: PubMed
    70. Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32. PMID: 17164380.
      View in: PubMed
    71. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80. PMID: 16990805.
      View in: PubMed
    72. Hwu P, Bedikian AY, Grimm EA. Challenges of chemosensitivity testing. Clin Cancer Res. 2006 Sep 15; 12(18):5258-9. PMID: 17000655.
      View in: PubMed
    73. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 2006 Aug 15; 119(4):861-6. PMID: 16557582.
      View in: PubMed
    74. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79. PMID: 16775224.
      View in: PubMed
    75. Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15. PMID: 16710719.
      View in: PubMed
    76. Li C, Liu Z, Wang LE, Strom SS, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901. PMID: 16621887.
      View in: PubMed
    77. Li C, Larson D, Zhang Z, Liu Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63. PMID: 16538172.
      View in: PubMed
    78. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of microglia isolated from human glioma patients. J Transl Med. 2006 Mar 30; 4:15. PMID: 16573834.
      View in: PubMed
    79. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 2006 Jun 29; 25(28):3956-62. PMID: 16474847.
      View in: PubMed
    80. Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. J Leukoc Biol. 2005 Sep; 78(3):745-52. PMID: 16000394.
      View in: PubMed
    81. Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, Zheng M. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005 May; 11(5):724-33. PMID: 15851011.
      View in: PubMed
    82. Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 2005 Mar; 5(2):103-15. PMID: 15810875.
      View in: PubMed
    83. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72. PMID: 15585417.
      View in: PubMed
    84. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95. PMID: 15564140.
      View in: PubMed
    85. Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA. HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC. Urologe A. 2004 Sep; 43 Suppl 3:S137. PMID: 15148575.
      View in: PubMed
    86. Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res. 2004 Aug 15; 10(16):5531-6. PMID: 15328193.
      View in: PubMed
    87. Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer. 2004 Aug 01; 101(3):596-603. PMID: 15274073.
      View in: PubMed
    88. Poindexter NJ, Sahin A, Hunt KK, Grimm EA. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 2004; 6(4):R408-15. PMID: 15217509.
      View in: PubMed
    89. Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res. 2004 Jun; 14(3):165-71. PMID: 15179184.
      View in: PubMed
    90. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004 May; 4(5):649-67. PMID: 15120650.
      View in: PubMed
    91. Tawa P, Hell K, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S. Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors. Cell Death Differ. 2004 Apr; 11(4):439-47. PMID: 14713960.
      View in: PubMed
    92. Sieger KA, Mhashilkar AM, Stewart A, Sutton RB, Strube RW, Chen SY, Pataer A, Swisher SG, Grimm EA, Ramesh R, Chada S. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004 Mar; 9(3):355-67. PMID: 15006602.
      View in: PubMed
    93. Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem. 2004 Jan 02; 279(1):288-98. PMID: 14576150.
      View in: PubMed
    94. Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA. High prevalence of hypothyroidism among patients with cutaneous melanoma. Oncol Rep. 2003 Sep-Oct; 10(5):1317-20. PMID: 12883700.
      View in: PubMed
    95. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S, Boquio A. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13. PMID: 12941841.
      View in: PubMed
    96. Mhashilkar AM, Stewart AL, Sieger K, Yang HY, Khimani AH, Ito I, Saito Y, Hunt KK, Grimm EA, Roth JA, Meyn RE, Ramesh R, Chada S. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther. 2003 Aug; 8(2):207-19. PMID: 12907143.
      View in: PubMed
    97. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, Dent P. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S23-37. PMID: 14508078.
      View in: PubMed
    98. Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA. Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy. J Urol. 2003 Jun; 169(6):2084-8. PMID: 12771724.
      View in: PubMed
    99. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Mol Cancer Ther. 2003 Jan; 2(1):9-17. PMID: 12533668.
      View in: PubMed
    100. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther. 2002 Oct; 1(12):1009-17. PMID: 12481423.
      View in: PubMed
    101. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, Ramesh R, Chada S. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002 Aug; 8(8):451-61. PMID: 12435856.
      View in: PubMed
    102. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93. PMID: 12095976.
      View in: PubMed
    103. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002 Jun 15; 168(12):6041-6. PMID: 12055212.
      View in: PubMed
    104. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of MDA-7 expression with progression of melanoma. J Clin Oncol. 2002 Feb 15; 20(4):1069-74. PMID: 11844832.
      View in: PubMed
    105. Ellerhorst JA, Cooksley CD, Grimm EA. Autoimmunity and hypothyroidism in patients with uveal melanoma. Melanoma Res. 2001 Dec; 11(6):633-7. PMID: 11725210.
      View in: PubMed
    106. Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer. 2001 Oct 01; 94(1):54-9. PMID: 11668478.
      View in: PubMed
    107. Mehta SK, Kaur I, Grimm EA, Smid C, Feeback DL, Pierson DL. Decreased non-MHC-restricted (CD56+) killer cell cytotoxicity after spaceflight. J Appl Physiol (1985). 2001 Oct; 91(4):1814-8. PMID: 11568167.
      View in: PubMed
    108. Yergey JA, Trimble LA, Silva J, Chauret N, Li C, Therien M, Grimm E, Nicoll-Griffith DA. In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization. Drug Metab Dispos. 2001 May; 29(5):638-44. PMID: 11302928.
      View in: PubMed
    109. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22. PMID: 11258775.
      View in: PubMed
    110. Licato LL, Prieto VG, Grimm EA. A novel preclinical model of human malignant melanoma utilizing bioreactor rotating-wall vessels. In Vitro Cell Dev Biol Anim. 2001 Mar; 37(3):121-6. PMID: 11370802.
      View in: PubMed
    111. Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). Bioorg Med Chem Lett. 2000 Dec 04; 10(23):2683-6. PMID: 11128651.
      View in: PubMed
    112. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW, Karl IE. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol. 2000 Dec; 1(6):496-501. PMID: 11101871.
      View in: PubMed
    113. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000 Dec; 6(12):4768-75. PMID: 11156233.
      View in: PubMed
    114. Caudell EG, Caudell JJ, Tang CH, Yu TK, Frederick MJ, Grimm EA. Characterization of human copine III as a phosphoprotein with associated kinase activity. Biochemistry. 2000 Oct 24; 39(42):13034-43. PMID: 11041869.
      View in: PubMed
    115. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000 Oct; 6(10):3895-903. PMID: 11051235.
      View in: PubMed
    116. Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol. 2000 Jun 15; 164(12):6244-51. PMID: 10843677.
      View in: PubMed
    117. Li CS, Black WC, Brideau C, Chan CC, Charleson S, Cromlish WA, Claveau D, Gauthier JY, Gordon R, Greig G, Grimm E, Guay J, Lau CK, Riendeau D, Thérien M, Visco DM, Wong E, Xu L, Prasit P. A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett. 1999 Nov 15; 9(22):3181-6. PMID: 10576684.
      View in: PubMed
    118. Licato LL, Grimm EA. Multiple interleukin-2 signaling pathways differentially regulated by microgravity. Immunopharmacology. 1999 Nov; 44(3):273-9. PMID: 10598884.
      View in: PubMed
    119. Leblanc Y, Roy P, Boyce S, Brideau C, Chan CC, Charleson S, Gordon R, Grimm E, Guay J, Léger S, Li CS, Riendeau D, Visco D, Wang Z, Webb J, Xu LJ, Prasit P. SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 02; 9(15):2207-12. PMID: 10465547.
      View in: PubMed
    120. Schroth MK, Grimm E, Frindt P, Galagan DM, Konno SI, Love R, Gern JE. Rhinovirus replication causes RANTES production in primary bronchial epithelial cells. Am J Respir Cell Mol Biol. 1999 Jun; 20(6):1220-8. PMID: 10340941.
      View in: PubMed
    121. Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, Owen-Schaub L, Buzaid AC, Grimm EA. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 1999 Jun; 9(3):261-72. PMID: 10465582.
      View in: PubMed
    122. Robinson EK, Sneige N, Grimm EA. Correlation of interleukin 6 with interleukin 1alpha in human mammary tumours, but not with oestrogen receptor expression. Cytokine. 1998 Dec; 10(12):970-6. PMID: 10049521.
      View in: PubMed
    123. Woods KV, Adler-Storthz K, Clayman GL, Francis GM, Grimm EA. Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. Cancer Res. 1998 Jul 15; 58(14):3142-9. PMID: 9679982.
      View in: PubMed
    124. Woods KV, El-Naggar A, Clayman GL, Grimm EA. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res. 1998 Jul 15; 58(14):3132-41. PMID: 9679981.
      View in: PubMed
    125. Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA. Cell cycle regulation of human pancreatic cancer by tamoxifen. Ann Surg Oncol. 1998 Jun; 5(4):342-9. PMID: 9641456.
      View in: PubMed
    126. Anderson CM, Buzaid AC, Sussman J, Lee JJ, Ali-Osman F, Braunschweiger PG, Plager C, Bedikian A, Papadopoulos N, Eton O, Legha SS, Grimm EA. Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res. 1998 Apr; 8(2):149-55. PMID: 9610868.
      View in: PubMed
    127. Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. Melanoma Res. 1998 Apr; 8(2):145-8. PMID: 9610867.
      View in: PubMed
    128. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, Grimm EA, Roth JA. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 1998 Feb; 5(2):189-95. PMID: 9578838.
      View in: PubMed
    129. Richardson MA, Post-White J, Grimm EA, Moye LA, Singletary SE, Justice B. Coping, life attitudes, and immune responses to imagery and group support after breast cancer treatment. Altern Ther Health Med. 1997 Sep; 3(5):62-70. PMID: 9287446.
      View in: PubMed
    130. Hamel P, Riendeau D, Brideau C, Chan CC, Desmarais S, Delorme D, Dubé D, Ducharme Y, Ethier D, Grimm E, Falgueyret JP, Guay J, Jones TR, Kwong E, McAuliffe M, McFarlane CS, Piechuta H, Roumi M, Tagari P, Young RN, Girard Y. Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010. J Med Chem. 1997 Aug 29; 40(18):2866-75. PMID: 9288168.
      View in: PubMed
    131. Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997 Aug; 15(8):2826-31. PMID: 9256125.
      View in: PubMed
    132. Frederick M, Grimm E, Krohn E, Smid C, Yu TK. Cytokine-induced cytotoxic function expressed by lymphocytes of the innate immune system: distinguishing characteristics of NK and LAK based on functional and molecular markers. J Interferon Cytokine Res. 1997 Aug; 17(8):435-47. PMID: 9282823.
      View in: PubMed
    133. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study. J Immunother. 1997 Jan; 20(1):79-87. PMID: 9101417.
      View in: PubMed
    134. Frederick MJ, Yu TK, Krohn EG, Johnston DA, Grimm EA. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells. Immunopharmacology. 1996 Nov; 35(2):83-102. PMID: 8956972.
      View in: PubMed
    135. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol. 1996 Aug; 105(2):344-52. PMID: 8706344.
      View in: PubMed
    136. Francis GM, Krohn EG, Woods KV, Buzaid AC, Grimm EA. Interleukin-6 production and secretion in human melanoma cell lines: regulation by interleukin-1. Melanoma Res. 1996 Jun; 6(3):191-201. PMID: 8819122.
      View in: PubMed
    137. Anderson CM, Buzaid AC, Grimm EA. Interaction of chemotherapy and biological response modifiers in the treatment of melanoma. Cancer Treat Res. 1996; 87:357-80. PMID: 8886461.
      View in: PubMed
    138. Frederick MJ, Rodriguez LV, Johnston DA, Grimm EA. Tumor target binding induces phosphorylation of two M(r) 65,000 lymphokine-activated killer proteins. Cancer Res. 1996 Jan 01; 56(1):127-37. PMID: 8548752.
      View in: PubMed
    139. Jung FA, Buzaid AC, Woods KV, Ross M, Grimm EA. Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Cancer Surv. 1996; 26:251-65. PMID: 8783578.
      View in: PubMed
    140. Ruff P, Grimm E, Kim A. Molecular analysis of a silent polymorphism in the PDZ domain of p55, the major palmitoylated erythrocyte membrane protein. Hematopathol Mol Hematol. 1996; 10(4):187-91. PMID: 9042661.
      View in: PubMed
    141. Frederick MJ, Rodriguez LV, Johnston DA, Darnay BG, Grimm EA. Characterization of the M(r) 65,000 lymphokine-activated killer proteins phosphorylated after tumor target binding: evidence that pp65a and pp65b are phosphorylated forms of L-plastin. Cancer Res. 1996 Jan 01; 56(1):138-44. PMID: 8548753.
      View in: PubMed
    142. Grimm E, Arbuthnot P. Rapid purification of recombinant Taq DNA polymerase by freezing and high temperature thawing of bacterial expression cultures. Nucleic Acids Res. 1995 Nov 11; 23(21):4518-9. PMID: 7501478.
      View in: PubMed
    143. Roussel E, Gingras MC, Grimm EA, Roth JA. High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. Cancer Immunol Immunother. 1995 Jul; 41(1):1-9. PMID: 7641214.
      View in: PubMed
    144. Tyler DS, Francis GM, Frederick M, Tran AH, Ordóñez NG, Smith JL, Eton O, Ross M, Grimm EA. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res. 1995 Apr; 15(4):331-40. PMID: 7627808.
      View in: PubMed
    145. Heaton KM, Grimm EA. Differential inhibition of lymphokine-activated killing, proliferation, and cytokine secretion by humanized antibodies against the low- and intermediate-affinity interleukin-2 receptors. A novel model for activation of human peripheral blood mononuclear cells by interleukin 2. Hum Immunol. 1995 Mar; 42(3):274-80. PMID: 7759316.
      View in: PubMed
    146. Zhang WW, Fujiwara T, Grimm EA, Roth JA. Advances in cancer gene therapy. Adv Pharmacol. 1995; 32:289-341. PMID: 7748797.
      View in: PubMed
    147. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994 Oct 05; 86(19):1458-62. PMID: 8089864.
      View in: PubMed
    148. Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Res. 1994 Oct; 4(5):327-30. PMID: 7858418.
      View in: PubMed
    149. Clayman GL, Stewart MG, Weber RS, el-Naggar AK, Grimm EA. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. Arch Otolaryngol Head Neck Surg. 1994 Jul; 120(7):743-8. PMID: 8018327.
      View in: PubMed
    150. Heaton KM, Ju G, Grimm EA. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Ann Surg Oncol. 1994 May; 1(3):198-203. PMID: 7842289.
      View in: PubMed
    151. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994 May 01; 54(9):2287-91. PMID: 8162565.
      View in: PubMed
    152. Koberda J, Przepiorka D, Moser RP, Grimm EE. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells. Lymphokine Cytokine Res. 1994 Apr; 13(2):139-45. PMID: 8061115.
      View in: PubMed
    153. Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA. Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int J Cancer. 1994 Mar 15; 56(6):834-9. PMID: 8119773.
      View in: PubMed
    154. Fujiwara T, Grimm EA, Roth JA. Gene therapeutics and gene therapy for cancer. Curr Opin Oncol. 1994 Jan; 6(1):96-105. PMID: 8204698.
      View in: PubMed
    155. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993 Sep 15; 53(18):4129-33. PMID: 8395976.
      View in: PubMed
    156. Heaton KM, Grimm EA. Cytokine combinations in immunotherapy for solid tumors: a review. Cancer Immunol Immunother. 1993 Sep; 37(4):213-9. PMID: 8348559.
      View in: PubMed
    157. Deen DF, Chiarodo A, Grimm EA, Fike JR, Israel MA, Kun LE, Levin VA, Marton LJ, Packer RJ, Pegg AE, et al. Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy. Organ System Program, National Cancer Institute. J Neurooncol. 1993 Jun; 16(3):243-72. PMID: 7905510.
      View in: PubMed
    158. Heaton KM, Ju G, Grimm EA. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 1993 Jun 01; 53(11):2597-602. PMID: 8495422.
      View in: PubMed
    159. Luo G, Niesel DW, Shaban RA, Grimm EA, Klimpel GR. Tumor necrosis factor alpha binding to bacteria: evidence for a high-affinity receptor and alteration of bacterial virulence properties. Infect Immun. 1993 Mar; 61(3):830-5. PMID: 8381771.
      View in: PubMed
    160. Heaton KM, Ju G, Morris DK, Delisio K, Bailon P, Grimm EA. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Cell Immunol. 1993 Mar; 147(1):167-79. PMID: 8462109.
      View in: PubMed
    161. Fujiwara T, Loudon WG, Grimm EA. Clones derived from human natural killer cells are susceptible to lysis by human interleukin-2-activated killer cells. Lymphokine Cytokine Res. 1993 Feb; 12(1):45-8. PMID: 8096153.
      View in: PubMed
    162. Koberda J, Grimm EA, Moser RP. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation. J Cancer Res Clin Oncol. 1993; 119(3):131-6. PMID: 8380285.
      View in: PubMed
    163. Lazenby AW, Roth JA, Owen-Schaub LB, Grimm EA. IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin). Cytokine. 1992 Nov; 4(6):479-87. PMID: 1337985.
      View in: PubMed
    164. Fujiwara T, Grimm EA. Specific inhibition of interleukin 1 beta gene expression by an antisense oligonucleotide: obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells. Cancer Res. 1992 Sep 15; 52(18):4954-9. PMID: 1387585.
      View in: PubMed
    165. Lagoo-Deenadayalan S, Lagoo AS, Hardy KJ, Grimm EA. Tumor recognition and lytic competence of IL-2-activated lymphocytes: regulation of both antibody-independent and -dependent cellular cytotoxicity via P75 IL-2 receptor. Lymphokine Cytokine Res. 1992 Aug; 11(4):207-13. PMID: 1420599.
      View in: PubMed
    166. Fujiwara T, Grimm EA. Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. Obligate paracrine pathway of IL-1 during lymphokine-activated killer cell induction. J Immunol. 1992 May 01; 148(9):2941-6. PMID: 1374105.
      View in: PubMed
    167. Owen-Schaub LB, Yonehara S, Crump WL, Grimm EA. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol. 1992 Mar; 140(1):197-205. PMID: 1371242.
      View in: PubMed
    168. List J, Moser RP, Steuer M, Loudon WG, Blacklock JB, Grimm EA. Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis: rapid induction of tumor necrosis factor alpha, interleukin 1 beta, interleukin 6, gamma-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 1992 Mar 01; 52(5):1123-8. PMID: 1737371.
      View in: PubMed
    169. Yang SC, Grimm EA, Roth JA. Combination immunotherapy for advanced lung cancer. J Natl Cancer Inst Monogr. 1992; (13):197-201. PMID: 1327033.
      View in: PubMed
    170. Yang SC, Fry KD, Grimm EA, Roth JA. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy. J Immunother (1991). 1991 Oct; 10(5):326-35. PMID: 1790140.
      View in: PubMed
    171. Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial. Cancer Res. 1991 Jul 15; 51(14):3669-76. PMID: 1648441.
      View in: PubMed
    172. Grimm EA, Owen-Schaub L. The IL-2 mediated amplification of cellular cytotoxicity. J Cell Biochem. 1991 Apr; 45(4):335-9. PMID: 2045426.
      View in: PubMed
    173. Grimm EA, Bruner JM, Carinhas J, Köppen JA, Loudon WG, Owen-Schaub L, Steck PA, Moser RP. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother. 1991; 32(6):391-9. PMID: 1848799.
      View in: PubMed
    174. Owen-Schaub LB, de Mars M, Murphy EC, Grimm EA. IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol. 1991 Jan; 132(1):193-200. PMID: 2065356.
      View in: PubMed
    175. Crump WL, Owen-Schaub LB, Grimm EA. Molecular identification of the human tumor necrosis factor receptor on interleukin-2-stimulated peripheral blood lymphocytes. Cell Immunol. 1990 Nov; 131(1):150-8. PMID: 2171784.
      View in: PubMed
    176. Schantz SP, Clayman G, Racz T, Grimm EA, Liu FJ, Lavedan P, Taylor D, Pellegrino C, Savage H. The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1990 Nov; 116(11):1302-8. PMID: 2242261.
      View in: PubMed
    177. Yang SC, Owen-Schaub LB, Roth JA, Grimm EA. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha. Cancer Res. 1990 Jun 15; 50(12):3526-32. PMID: 2160321.
      View in: PubMed
    178. Irimura T, McIsaac AM, Carlson DA, Yagita M, Grimm EA, Menter DG, Ota DM, Clary KR. Soluble factor in normal tissues that stimulates high-molecular-weight sialoglycoprotein production by human colon carcinoma cells. Cancer Res. 1990 Jun 01; 50(11):3331-8. PMID: 2334927.
      View in: PubMed
    179. Yang SC, Fry KD, Grimm EA, Roth JA. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha. Arch Surg. 1990 Feb; 125(2):220-5. PMID: 2137327.
      View in: PubMed
    180. Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, Grimm EA, Hong WK, Roth JA. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha. J Thorac Cardiovasc Surg. 1990 Jan; 99(1):8-12; discussion 12-3. PMID: 2152954.
      View in: PubMed
    181. Owen-Schaub LB, De Mars M, Murphy EC, Grimm EA. TNF-beta (lymphotoxin) strongly upregulates TNF-alpha gene expression in human peripheral blood lymphocytes. Lymphokine Res. 1990; 9(4):491-7. PMID: 1708843.
      View in: PubMed
    182. Wolf JA, Grimm EA. Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes. Curr Opin Oncol. 1989 Dec; 1(2):249-57. PMID: 2489968.
      View in: PubMed
    183. Owen-Schaub LB, Crump WL, Morin GI, Grimm EA. Regulation of lymphocyte tumor necrosis factor receptors by IL-2. J Immunol. 1989 Oct 01; 143(7):2236-41. PMID: 2550551.
      View in: PubMed
    184. Yagita M, Itoh K, Tsudo M, Schaub LB, Platsoucas CD, Balch CM, Grimm EA. Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. Cancer Res. 1989 Mar 01; 49(5):1154-9. PMID: 2783885.
      View in: PubMed
    185. Blacklock JB, Grimm EA. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system. Immunol Ser. 1989; 48:93-9. PMID: 2488328.
      View in: PubMed
    186. Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother. 1989; 29(3):193-8. PMID: 2543502.
      View in: PubMed
    187. Crump WL, Owen-Schaub LB, Grimm EA. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res. 1989 Jan 01; 49(1):149-53. PMID: 2783241.
      View in: PubMed
    188. Owen-Schaub LB, Grimm EA. Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines. Immunol Ser. 1989; 48:19-35. PMID: 2488321.
      View in: PubMed
    189. George RE, Loudon WG, Moser RP, Bruner JM, Steck PA, Grimm EA. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg. 1988 Sep; 69(3):403-9. PMID: 3261328.
      View in: PubMed
    190. Wolf JA, Grimm EA. Activated lymphocyte cytotoxicity: concepts and confusions. Ann Inst Pasteur Immunol. 1988 Jul-Aug; 139(4):435-8. PMID: 3048320.
      View in: PubMed
    191. Owen-Schaub LB, Gutterman JU, Grimm EA. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. Cancer Res. 1988 Feb 15; 48(4):788-92. PMID: 3257408.
      View in: PubMed
    192. Owen-Schaub LB, Loudon WG, Yagita M, Grimm EA. Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors. Cell Immunol. 1988 Jan; 111(1):235-46. PMID: 3123071.
      View in: PubMed
    193. Grimm EA, Owen-Schaub LB, Loudon WG, Yagita M. Lymphokine-activated killer cells. Induction and function. Ann N Y Acad Sci. 1988; 532:380-6. PMID: 3140701.
      View in: PubMed
    194. Yagita M, Grimm EA. Current understanding of the lymphokine-activated killer cell phenomenon. Prog Exp Tumor Res. 1988; 32:213-26. PMID: 3131833.
      View in: PubMed
    195. Grimm EA, Crump WL, Durett A, Hester JP, Lagoo-Deenadalayan S, Owen-Schaub LB. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother. 1988; 27(1):53-8. PMID: 3260821.
      View in: PubMed
    196. Tsudo M, Goldman CK, Bongiovanni KF, Chan WC, Winton EF, Yagita M, Grimm EA, Waldmann TA. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A. 1987 Aug; 84(15):5394-8. PMID: 3110786.
      View in: PubMed
    197. Jacobs SK, Parham CW, Holcomb B, Ikejiri B, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell mediated killing of human glioma: effect of pretreating glioma with various membrane modifying agents. J Neurooncol. 1987; 5(1):5-10. PMID: 3037036.
      View in: PubMed
    198. Grimm EA. Interleukin-2 activated cytotoxic lymphocytes and their application in the intraoperative immunotherapy of local tumors. Prog Clin Biol Res. 1987; 244:185-95. PMID: 3498948.
      View in: PubMed
    199. Grimm EA. Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta. 1986 Dec 17; 865(3):267-79. PMID: 3539198.
      View in: PubMed
    200. Lanza LA, Wilson DJ, Ikejiri B, Roth JA, Grimm EA. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells. J Immunol. 1986 Oct 15; 137(8):2716-20. PMID: 3489774.
      View in: PubMed
    201. Jacobs SK, Wilson DJ, Melin G, Parham CW, Holcomb B, Kornblith PL, Grimm EA. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies. Neurol Res. 1986 Jun; 8(2):81-7. PMID: 2875409.
      View in: PubMed
    202. Jacobs SK, Melin G, Holcomb B, Parham CW, Kornblith PL, Grimm EA. Lymphokine activated killer (LAK) cell-mediated lysis of murine glioma: trypsin-chymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells. Brain Res. 1986 May 07; 372(2):386-9. PMID: 3486696.
      View in: PubMed
    203. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986 May; 64(5):743-9. PMID: 3517250.
      View in: PubMed
    204. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res. 1986 Apr; 46(4 Pt 2):2101-4. PMID: 3512079.
      View in: PubMed
    205. Yagita M, Grimm EA. Inhibition of in vitro LAK generation by OK-432. Cancer Immunol Immunother. 1986; 23(3):207-13. PMID: 3491681.
      View in: PubMed
    206. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J Neurosurg. 1986 Jan; 64(1):114-7. PMID: 3001247.
      View in: PubMed
    207. Grimm EA, Jacobs SK, Lanza LA, Melin G, Roth JA, Wilson DJ. Interleukin 2-activated cytotoxic lymphocytes in cancer therapy. Symp Fundam Cancer Res. 1986; 38:209-19. PMID: 3489259.
      View in: PubMed
    208. Grimm EA, Wilson DJ. The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes. Cell Immunol. 1985 Sep; 94(2):568-78. PMID: 3928175.
      View in: PubMed
    209. Lotze MT, Rayner AA, Grimm EA. Problems with the isolation of lymphoid clones with reactivity to human tumors. Behring Inst Mitt. 1985 Aug; (77):105-14. PMID: 3936471.
      View in: PubMed
    210. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst. 1985 Jul; 75(1):67-75. PMID: 2989604.
      View in: PubMed
    211. Grimm EA, Muul LM, Wilson DJ. The differential inhibitory effects exerted by cyclosporine and hydrocortisone on the activation of human cytotoxic lymphocytes by recombinant interleukin-2 versus allospecific CTL. Transplantation. 1985 May; 39(5):537-40. PMID: 3158107.
      View in: PubMed
    212. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 1985 Mar 15; 55(6):1327-33. PMID: 3871657.
      View in: PubMed
    213. Rong GH, Grimm EA, Sindelar WF. An enzymatic method for the consistent production of monodispersed viable cell suspensions from human solid tumors. J Surg Oncol. 1985 Feb; 28(2):131-3. PMID: 2982062.
      View in: PubMed
    214. Grimm EA, Rayner AA, Wilson DJ. Human NK resistant tumor cell lysis is effected by IL-2 activated killer cells. Adv Exp Med Biol. 1985; 184:161-75. PMID: 2994409.
      View in: PubMed
    215. Weidler B, von Bormann B, Muhrer KH, Kothe M, Grimm E, Boldt J, Kling D, Hempelmann G. [Effect of postoperative parenteral feeding on protein metabolism in heart surgery patients. A comparative study]. Infusionsther Klin Ernahr. 1984 Aug; 11(4):235-41. PMID: 6434423.
      View in: PubMed
    216. Perelson AS, Macken CA, Grimm EA, Roos LS, Bonavida B. Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol. 1984 May; 132(5):2190-8. PMID: 6609191.
      View in: PubMed
    217. Rosenberg SA, Grimm EA, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark DF. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science. 1984 Mar 30; 223(4643):1412-4. PMID: 6367046.
      View in: PubMed
    218. Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 1984 Feb 15; 53(4):896-905. PMID: 6692292.
      View in: PubMed
    219. Grimm EA, Vose BM, Chu EW, Wilson DJ, Lotze MT, Rayner AA, Rosenberg SA. The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues. Cancer Immunol Immunother. 1984; 17(2):83-9. PMID: 6205746.
      View in: PubMed
    220. Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983 Oct 01; 158(4):1356-61. PMID: 6413638.
      View in: PubMed
    221. Bonavida B, Bradley TP, Grimm EA. The single-cell assay in cell-mediated cytotoxicity. Immunol Today. 1983 Jul; 4(7):196-200. PMID: 25289827.
      View in: PubMed
    222. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1983 Mar 01; 157(3):884-97. PMID: 6601174.
      View in: PubMed
    223. Mazumder A, Grimm EA, Rosenberg SA. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J Immunol. 1983 Feb; 130(2):958-64. PMID: 6848602.
      View in: PubMed
    224. Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunol Immunother. 1983; 15(1):1-10. PMID: 6603260.
      View in: PubMed
    225. Roth JA, Grimm EA, Osborne BA, Putnam JB, Davidson DD, Ames RS. Suppressive immunoregulatory factors produced by tumors. Lymphokine Res. 1983; 2(2):67-73. PMID: 6332246.
      View in: PubMed
    226. Bonavida B, Bradley TP, Grimm EA. Frequency determination of killer cells by a single-cell cytotoxic assay. Methods Enzymol. 1983; 93:270-80. PMID: 6408349.
      View in: PubMed
    227. Rosenberg SA, Eberlein TJ, Grimm EA, Lotze MT, Mazumder A, Rosenstein M. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery. 1982 Aug; 92(2):328-36. PMID: 6980492.
      View in: PubMed
    228. Grimm EA, Mazumder A, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor. Cell Immunol. 1982 Jul 01; 70(2):248-59. PMID: 6812964.
      View in: PubMed
    229. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 01; 155(6):1823-41. PMID: 6176669.
      View in: PubMed
    230. Roth JA, Grimm EA, Gupta RK, Ames RS. Immunoregulatory factors derived from human tumors. I. Immunologic and biochemical characterization of factors that suppress lymphocyte proliferative and cytotoxic responses in vitro. J Immunol. 1982 May; 128(5):1955-62. PMID: 6460814.
      View in: PubMed
    231. Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA. Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins. Cancer Res. 1982 Mar; 42(3):913-8. PMID: 7059990.
      View in: PubMed
    232. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981 Nov; 41(11 Pt 1):4420-5. PMID: 6975652.
      View in: PubMed
    233. Strausser JL, Mazumder A, Grimm EA, Lotze MT, Rosenberg SA. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol. 1981 Jul; 127(1):266-71. PMID: 7195411.
      View in: PubMed
    234. Targan S, Grimm E, Bonavida B. A single cell marker of active NK cytotoxicity: only a fraction of target binding lymphocytes are killer cells. J Clin Lab Immunol. 1980 Nov; 4(3):165-8. PMID: 7205938.
      View in: PubMed
    235. Neville ME, Grimm E, Bonavida B. Frequency determination of K cells by a single cell cytotoxic assay. J Immunol Methods. 1980; 36(3-4):255-68. PMID: 7430654.
      View in: PubMed
    236. Grimm E, Bonavida B. Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol. 1979 Dec; 123(6):2861-9. PMID: 315432.
      View in: PubMed
    237. Grimm EA, Thoma JA, Bonavida B. Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol. 1979 Dec; 123(6):2870-7. PMID: 315433.
      View in: PubMed
    238. Grimm EA, Bonavida B. Studies on the induction and expression of T cell-mediated immunity. IX. Activation of alloimmune memory lymphocytes into specific secondary CTL by syngeneic NAGO-oxidized stimulator cells. J Immunol. 1979 Nov; 123(5):2026-33. PMID: 314955.
      View in: PubMed
    239. Grimm E, Price Z, Bonavida B. Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. Cell Immunol. 1979 Aug; 46(1):77-99. PMID: 314849.
      View in: PubMed
    240. Grimm EA, Bonavida B. Studies of the induction and expression of T cell mediated immunity. VI. Heterogeneity of lytic efficiency exhibited by isolated cytotoxic T lymphocytes prepared from highly enriched populations of effector-target conjugates. J Immunol. 1977 Sep; 119(3):1041-7. PMID: 302269.
      View in: PubMed
    241. Bonavida B, Grimm E, Kedar E. Frequency of thymus-dependent plaque-forming units: direct estimation by a modified plaque assay. Transplant Proc. 1977 Mar; 9(1):705-8. PMID: 325802.
      View in: PubMed
    242. Roth JA, Grimm EA, Morton DL. A rapid assay for stimulation of human lymphocytes by tumor-associated antigens. Cancer Res. 1976 Sep; 36(9 pt.1):3001-10. PMID: 975069.
      View in: PubMed
    243. Grimm EA, Silver HK, Roth JA, Chee DO, Gupta RK, Morton DL. Detection of tumor-associated antigen in human melanoma cell line supernatants. Int J Cancer. 1976 May 15; 17(5):559-64. PMID: 1270174.
      View in: PubMed
    244. Roth JA, Golub SH, Grimm EA, Eilber FR, Morton DL. Effects of operation on immune response in cancer patients: sequential evaluation of in vitro lymphocyte function. Surgery. 1976 Jan; 79(1):46-51. PMID: 128842.
      View in: PubMed
    245. Ring K, Grimm E, Schwarz M. [Interrelationship between the transport of L-aspartate and potassium ions into the cell (author's transl)]. Arzneimittelforschung. 1976; 26(6):1195-201. PMID: 989415.
      View in: PubMed
    246. Roth JA, Golub SH, Grimm EA, Eilber FR, Morton DL. Effect of surgery on in vitro lymphocyte function. Surg Forum. 1974; 25(0):102-4. PMID: 4439131.
      View in: PubMed
    247. Musser MJ, Grimm EA. DETERMINATION OF ADRENERGIC AND CHOLINERGIC SUBSTANCES IN THE BLOOD OF MAN. J Clin Invest. 1949 Jul; 28(4):653-60. PMID: 16695722.
      View in: PubMed
    248. Harris TN, Grimm E, Mertens E, Ehrich WE. THE ROLE OF THE LYMPHOCYTE IN ANTIBODY FORMATION. J Exp Med. 1945 Jan 01; 81(1):73-83. PMID: 19871445.
      View in: PubMed
    249. Reduction of pulmonary metastases following in vivo administration of anti-CD3, interleukin-2, and tumor necrosis factor-α in mice. Surgical Forum. 40:423-425.
    250. Enhancement of lymphokine-activated killer cell cytotoxicity with interleukin-2, tumor necrosis factor-alpha, and OKT3 against primary lung cancer targets. Surgical Forum. 39:454-456.
    251. Immunologic profile of a patient with dyskeratosis congenita. Immunology and Allergy Practice. 14:150-157.
    252. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.
    253. The single-cell assay in cell-mediated cytotoxicity. Immunology Today. 4:196-200.
    254. Dual roles of RNF2 in melanoma progression. Cancer Discovery. 5:1314-1327.
    255. Lymphokine-activated killer cell (LAK) lysis of human glioblastoma in vitro.
    256. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6.
    257. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research.
    258. Braf mutations are associated with high levels of phosphorylated RKIP in melanoma cell lines. Forum on Immunopathological Diseases and Therapeutics. 2:189-194.
    259. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (United States).
    260. Immunology comes full circle in melanoma while specific immunity is unleashed to eliminate metastatic disease, inflammatory products of innate immunity promote resistance. Critical Reviews in Oncogenesis. 21:57-63.
    261. Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell and Melanoma Research. 28:357-359.
    262. Annals of the New York Academy of Sciences. 532:480-481.
    263. Regression of radiation- and chemotherapy-resistant non-small cell lung cancer treated with combination immunotherapy. Cancer Bulletin. 43:181-184.
    264. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (United States). 95.
    265. Biologic therapy for brain tumors. Cancer Bulletin. 43:117-126.
    266. [19] Frequency determination of killer cells by a single-cell cytotoxic assay. Methods. 93:271-280.
    267. A Rapid Assay for Stimulation of Human Lymphocytes by Tumor-associated Antigens. Cancer Research. 36:3001-3010.
    268. Hematopoietic Growth Factors and Cytokines. 605-619.
    269. Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine. 4.
    270. Biochemotherapy in the treatment of advanced melanoma. Drug News and Perspectives. 8:480-485.
    271. Interleukin-2 and cytotoxic lymphocyte therapy of primary and metastatic brain tumors. Fernstrom Foundation Series. 14:527-538.
    272. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma Research.
    273. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ (Journal of Investigative Dermatology (2015) 135 (2901) DOI. Journal of Investigative Dermatology. 135:2901.
    274. Uveal melanoma. Cancer.
    275. Demonstration of shared recognition and lysis of autologous and allogeneic fresh human tumors by cloned lymphokine-activated killer cells. Surgical Forum. VOL. 35:415-417.
    276. Erratum. Journal of Investigative Dermatology. 135:2775-2784.
    277. Studies on the immunotherapy of human gliomas using autologous lymphokine-activated killer cells. Surgical Forum. VOL. 36:504-506.
    278. Phase I clinical trial of infusion into cancer patients of autologous lymphocytes activated in vitro with lectins.
    279. Effects of low dose OKT3 induction on the antitumor immune response in cancer patients receiving interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF). Surgical Forum. 41:434-436.
    280. Hematopoietic Growth Factors and Cytokines.
    281. Biologic therapy for lung cancer. Cancer Bulletin. 43:100-108.
    282. Annals of the New York Academy of Sciences. 532:472-474.
    283. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. 15:2442-2454.
    284. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7:484-492.
    GRIMM's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description